{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008282","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.233498+00:00","generated_at":"2026-06-18T01:04:02.036206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nuvalent reports net loss of $81.9M for FY22; cash runway into H2 2025","bullets":["Cash, cash equivalents and marketable securities $472.2M as of Dec 31, 2022; expected to fund operations into H2 2025.","Net loss of $26.1M in Q4 2022 and $81.9M for full year 2022; R&D expenses $63.7M (FY) vs $35.6M in 2021.","Pipeline progress: NVL-520 Phase 1 data supportive of best-in-class profile in ROS1+ NSCLC; NVL-655 Phase 1 enrolling; NVL-330 (HER2 exon20) nominated as development candidate.","Leadership promotions: Henry Pelish to SVP Drug Discovery; John Soglia to SVP Translational Development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008282","json":"https://secwatch.observer/filing/0000950170-23-008282.json","markdown":"https://secwatch.observer/filing/0000950170-23-008282.md","text":"https://secwatch.observer/filing/0000950170-23-008282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023008282/0000950170-23-008282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023008282/nuvl-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T01:04:02.036206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f360afe65c21a97313e398e634ca03b9311ada3","claim":"Nuvalent, Inc. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"announced its financial results for the quarter and year ended December 31, 2023, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023008282/0000950170-23-008282-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}